Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $25.24 in the prior trading day, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $24.69, down -2.18%. In other words, the price has decreased by -$2.18 from its previous closing price. On the day, 1.07 million shares were traded. ARWR stock price reached its highest trading level at $25.19 during the session, while it also had its lowest trading level at $24.01.
Ratios:
Our goal is to gain a better understanding of ARWR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.31 and its Current Ratio is at 8.31. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.82.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’24 when Vakiener Victoria sold 1,799 shares for $23.31 per share. The transaction valued at 41,935 led to the insider holds 30,205 shares of the business.
Hamilton James C sold 6,000 shares of ARWR for $168,180 on Apr 01 ’24. The Chief Discovery/Trans Medicine now owns 204,851 shares after completing the transaction at $28.03 per share. On Mar 20 ’24, another insider, Lu Hongbo, who serves as the Director of the company, bought 1,000 shares for $27.50 each. As a result, the insider paid 27,500 and bolstered with 33,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3134815232 and an Enterprise Value of 2957055744. For the stock, the TTM Price-to-Sale (P/S) ratio is 86.45 while its Price-to-Book (P/B) ratio in mrq is 6.34. Its current Enterprise Value per Revenue stands at 83.361 whereas that against EBITDA is -6.459.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $39.83, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 0.58%, while the 200-Day Moving Average is calculated to be -11.51%.
Shares Statistics:
The stock has traded on average 1.06M shares per day over the past 3-months and 1089750 shares per day over the last 10 days, according to various share statistics. A total of 124.20M shares are outstanding, with a floating share count of 117.64M. Insiders hold about 5.28% of the company’s shares, while institutions hold 77.20% stake in the company. Shares short for ARWR as of 1715731200 were 9343977 with a Short Ratio of 8.81, compared to 1713139200 on 8866496. Therefore, it implies a Short% of Shares Outstanding of 9343977 and a Short% of Float of 8.8199995.
